Senti Biosciences (SNTI) to Release Earnings on Thursday

Senti Biosciences (NASDAQ:SNTI - Get Free Report) is projected to release its earnings data before the market opens on Thursday, May 8th. Analysts expect Senti Biosciences to post earnings of ($0.56) per share and revenue of $1.30 million for the quarter.

Senti Biosciences (NASDAQ:SNTI - Get Free Report) last announced its earnings results on Thursday, March 20th. The company reported ($0.67) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.13) by $2.46. The company had revenue of $5.86 million during the quarter, compared to analysts' expectations of $2.80 million. On average, analysts expect Senti Biosciences to post $-15 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Senti Biosciences Price Performance

SNTI stock traded up $0.07 during mid-day trading on Friday, hitting $3.32. 42,230 shares of the stock were exchanged, compared to its average volume of 801,234. The business has a fifty day moving average price of $3.48 and a 200 day moving average price of $3.64. Senti Biosciences has a 12 month low of $1.52 and a 12 month high of $16.94. The stock has a market capitalization of $86.33 million, a price-to-earnings ratio of -0.21 and a beta of 2.32.

Analyst Upgrades and Downgrades

Separately, Chardan Capital reissued a "buy" rating and set a $12.00 price target on shares of Senti Biosciences in a research note on Friday.

About Senti Biosciences

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.